発作を起こしやすい脳領域を特定するための脳波と脳磁図の同時実施

Executive Industry Relevance

Simultaneous EEG and MEG acquisition with advanced detection of interictal epileptiform discharges (IEDs) and high-frequency oscillations (HFOs) enables precise localization of seizure-prone brain regions. This workflow enhances predictive confidence in neurobiological target identification and supports mechanistic de-risking in CNS drug discovery. Integrating quantitative neuroimaging biomarkers at early discovery inflection points informs portfolio triage and translational continuity.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of neuronal network dysfunction through detection of IEDs and HFOs.
• Supports functional target validation by mapping seizure-prone regions with high spatial precision.
• Facilitates mechanistic de-risking by distinguishing true neuronal signals from artifacts using peripheral recordings.
• Improves predictive confidence for CNS target selection and prioritization.

Screening & Assay Development

• Provides validated neurophysiological readouts for downstream compound screening workflows.
• Standardizes detection thresholds for IEDs and HFOs, supporting reproducibility across studies.
• Enables quantitative assessment of neuronal activity for assay development and optimization.
• Prepares robust biological systems for reliable evaluation of candidate interventions.

Translational & Preclinical Research

• Aligns neurophysiological biomarkers with disease-relevant endpoints for translational research.
• Ensures continuity from early discovery through preclinical validation by localizing functional brain regions.
• Supports risk-adjusted advancement decisions based on quantitative mapping of seizure-prone zones.
• Provides mechanistic insights that inform preclinical model selection and validation.

Pipeline & Workflow Integration

This method integrates into the discovery continuum from early target validation through preclinical research, providing quantitative neuroimaging outputs for decision-making.

• Discovery Biology: Supports hypothesis testing and pathway clarification by mapping abnormal neuronal activity.
• Screening: Delivers reproducible, quantitative readouts of IEDs and HFOs for assay readiness.
• Analytics: Generates 3D brain maps and statistical outputs for cross-condition comparison.
• Translational Research: Aligns neurophysiological biomarkers with preclinical endpoints for disease relevance.
• Enterprise Reuse: Establishes a reusable workflow for CNS biomarker discovery and validation.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in CNS target validation.
• Operational Value: Standardizes neuroimaging protocols and ensures reproducibility across studies.
• Strategic Value: Enables informed go/no-go decisions and capital-efficient portfolio management.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of CNS programs.

Implementation Considerations

• Requires expertise in EEG, MEG, and advanced neuroimaging analysis.
• Demands access to high-fidelity instrumentation and computational infrastructure for data processing.
• Necessitates cross-team standardization of detection algorithms and artifact exclusion protocols.
• Adaptation may be needed for different patient populations or neurological models.
• Artifact exclusion and thresholding must be rigorously validated to ensure data integrity.

Biopharma FAQs